Royalty Pharma Net Long-Term Debt 2019-2024 | RPRX
Royalty Pharma annual/quarterly net long-term debt history and growth rate from 2019 to 2024. Net long-term debt can be defined as the net amount of long term debt issued and repaid. This field is either calculated as the sum of the long term debt fields or used if a company does not report debt issued and repaid separately
- Royalty Pharma net long-term debt for the quarter ending December 31, 2024 was $1.471B, a 247.12% decline year-over-year.
- Royalty Pharma net long-term debt for the twelve months ending December 31, 2024 was $4.414B, a 320.69% decline year-over-year.
- Royalty Pharma annual net long-term debt for 2024 was $1.471B, a 247.12% decline from 2023.
- Royalty Pharma annual net long-term debt for 2023 was $-1B, a 0% decline from 2022.
- Royalty Pharma annual net long-term debt for 2022 was $0B, a 100% decline from 2021.
| Royalty Pharma Annual Net Long-Term Debt (Millions of US $) |
|
|---|---|
| 2024 | $1,471 |
| 2023 | $-1,000 |
| 2022 | $N/A |
| 2021 | $1,273 |
| 2020 | $681 |
| 2019 | $-294 |
| 2018 | $-294 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Finance | FIN-MISC SVCS | $18.960B | $2.264B |
| Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko and Trikafta, and development-stage product candidates. Royalty Pharma plc is based in NEW YORK. | |||